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Introduction
In a cycle that repeats several billions of 
times per day in the healthy human adult, 
dead cells attract scavengers—either 
neighboring cells or professional phago-
cytes (mostly macrophages)—that medi-
ate their engulfment and digestion with-
out leaving any trace, neither corpses 
nor graveyards. This interaction between 
dying cells and phagocytes reflects the 
baseline contribution of inflammation to 
normal tissue homeostasis (Metchnikoff 
and Ehrlich, 1990). Perturbations of this 
equilibrium due to the inappropriate 
death of noninflammatory cells or insuffi-
cient clearance of dying or dead cells by 
phagocytes can lead to autoimmune dis-
ease, as well as to pathological inflam-
mation. Once inflammation is manifest 
or an immune response is mounted, 
their resolution or decline, respectively, 
requires the apoptosis and clearance of 
effector cells (Medzhitov, 2008). There-
fore, understanding the pathways for cell 
death and clearance is instrumental for 
the exploration and therapeutic manipu-
lation of inflammation.
When cells die in response to micro-
bial infection, the local presence of 
pathogen-associated molecular patterns 
(PAMPs) triggers the innate (and even-
tually the cognate) immune response, 
marking the distinction between innocu-
ous cell death (without PAMPs), which 
should be handled without an inflam-
matory response, and pathological 
cell death (with PAMPs), which should 
induce a response. In this Essay, we 
concentrate on cell death occurring in 
the absence of PAMPs and its impact on 
inflammation caused in the absence of 
infection. The generally accepted para-
digm is that apoptosis, the physiological 
form of cell death, occurs without (and 
sometimes even with the active seques-
tration of) danger-associated molecular 
patterns (DAMPs). Apoptotic corpses 
can suppress the transcription of proin-
flammatory cytokine genes, promote the 
secretion of anti-inflammatory cytokines 
by phagocytes, and cause antigen-pre-
senting cells to present dead-cell-anti-
gen in a manner that promotes immuno-
logical tolerance. In contrast, necrosis, 
which often results from nonphysiologi-
cal damage, leads to the exposure of 
DAMPs and consequent activation of 
inflammatory and immune effectors 
because DAMPs act on the same pattern 
recognition receptors as PAMPs (Kono 
and Rock, 2008). Nevertheless, the 
appealing notion that accidental necro-
sis would always elicit inflammation 
and potent immune responses whereas 
programmed apoptosis would be anti-
inflammatory and tolerogenic is an over-
simplification. For instance, this concept 
is challenged by the fact that in some 
cases, antigen from apoptotic cells trig-
gers efficient immune responses (Green 
et al., 2009) and that necrosis can be 
executed in a programmed, highly regu-
lated fashion (Garg et al., 2009).
Here, we explore the notion that it is 
the context in which cell death occurs 
that determines its impact on the inflam-
matory and immune response. We pro-
pose that particular combinations of cell 
death-associated molecules released 
from or exposed at the surface of dying 
or dead cells act like a combinatorial 
code to unlock distinct inflammatory and 
immune responses.
Cell Death-Associated Molecules
Dying or dead cells expose or release 
numerous molecules to attract inflam-
matory effectors (“find-me” signals) 
and to foster their engulfment (“eat-me” 
signals) so that the release of potential 
autoantigens is avoided. Here we enu-
merate some of the common character-
istics of cell death-associated molecules 
(Table S1 available online).
“Find-Me” Signals for Chemotaxis
As cells die, they can release several fac-
tors that attract professional phagocytes, 
in particular macrophages. Among the 
most important find-me signals are nucle-
otides (such as ATP and UTP), which are 
released either through an active exocyto-
sis-like process before the plasma mem-
brane becomes permeable or passively 
when cells lose their integrity (Ghiringhelli 
et al., 2009). Through its action on cell 
surface purinergic receptors, in particular 
P2Y2, released ATP attracts macrophages 
(Elliott et al., 2009). ATP also activates the 
NLRP3 inflammasome through its action 
on P2RX7, thus stimulating the production 
of interleukin 1β (IL-1β) by macrophages 
or dendritic cells (Ghiringhelli et al., 2009). 
Apoptotic cells release lipid mediators 
such as lysophosphatidylcholine and 
sphingosine-1-phosphate (which presum-
ably can be released before the plasma 
membrane breaks down). These lipids 
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attract macrophages and simultaneously 
may inhibit the release of proinflamma-
tory cytokines (HMGB1, TNF-α, IL-12) and 
enhance the liberation of immunosup-
pressive factors (IL-10, PGE2) from mac-
rophages (Munoz et al., 2009). Cleaved 
proteins that result from the action of 
caspases (such as endothelial monocyte-
activating polypeptide II) may also serve 
as chemoattractants at a later stage of 
cell death when they are released through 
the permeabilized plasma membrane 
(Munoz et al., 2009) and hence act as a 
backup signal when apoptotic cells have 
not been removed before they undergo 
secondary necrosis. Lactoferrin secreted 
by apoptotic cells serves as a “keep-out” 
signal to specifically suppress the poten-
tially harmful recruitment of neutrophil 
granulocytes (Bournazou et al., 2009). 
Altogether, it appears that dying cells can 
emit a number of redundant signals that 
facilitate the chemotactic recruitment of 
specific phagocytes (Figure 1A).
“Eat-Me” Signals for Engulfment
The physicochemical properties of 
cell surfaces change as cells die and 
are engulfed by neighboring cells (for 
instance by epithelial cells or fibro-
blasts), macrophages, or immature den-
dritic cells. This process is facilitated 
by serum-derived proteins, known as 
opsonins, including growth arrest-spe-
cific gene 6 (Gas6), milk fat globule EGF/
factor VIII (MFG-E8), β2-glycoprotein 1 
(β2GP1), and annexin V. These proteins 
Figure 1. Cell Death-Associated Molecules
(A) Find-me signals. Chemotactic and chemotropic (“find-me”) signals cause mobile phagocytic cells to migrate as a whole (chemotaxis) or extended part of the 
cell (chemotropism) toward the dying cell. Distinct find-me signals are generated during apoptosis and secondary necrosis and might attract different phago-
cytes. “Keep-out” signals repel defined inflammatory cells. Some find-me signals have anti-inflammatory effects, while others have proinflammatory potential. 
(B) Eat-me signals. The exposure of engulfment (“eat-me”) signals, combined with the downregulation of repulsion (“don’t eat-me”) signals, facilitates the 
engulfment of dying cells. Some eat-me signals (such as calreticulin) can be exposed before the most conserved signal, phosphatidylserine (PS), exposure oc-
curs. Others manifest later, for instance when the glycocalix changes. A number of eat-me signals require opsonins as molecular bridges to phagocytes. Some 
receptors that perceive eat-me signals transmit anti-inflammatory signals. 
(C) Hidden molecules. Primary or secondary necrosis causes the release of multiple molecules that are usually secluded (“hidden”) within the intact plasma 
membrane and that can be perceived by pattern recognition receptors once they become accessible or are released. Some hidden molecules can mediate 
predominantly immunosuppressive effects. Moreover, phagocytes express TAM receptors that, upon ligation by HMGB1, HSP70, or HSP90, have anti-inflam-
matory effects.
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bind to surface-exposed phosphatidyl-
serine residues. Phosphatidylserine is 
usually only present in the inner leaflet 
of the plasma membrane. However, the 
death-associated increase in entropy, 
aided by the inactivation of specific lipid 
transferases, culminates in the surface 
exposure of phosphatidylserine, which 
together with other lipids, can become 
oxidized. The exposure of phosphatidyl-
serine is efficiently induced upon cas-
pase activation, as well as in a slower, 
caspase-independent fashion, in devel-
opmental and homeostatic cell death 
(Table S1). Several receptors on phago-
cytes assure the engulfment of cells 
exposing phosphatidylserine, including 
T cell immunoglobulin domain and mucin 
domain protein 4 (TIM4), the scavenger 
receptors CD36 and steroid receptor 
activator 1 (which both bind oxidized 
lipids), and the TAM family of receptors 
(which bind Gas6) comprised by Tyro2, 
Axl, and Mer. These latter receptors can 
suppress Toll-like receptor (TLR) signal-
ing (Lemke and Rothlin, 2008), revealing 
one mechanism by which apoptotic cells 
suppress proinflammatory signals.
Before phosphatidylserine is exposed, 
cells can specifically translocate calre-
ticulin from the endoplasmic reticulum 
(ER) lumen to the cell surface (Panare-
takis et al., 2009). When calreticulin is 
surface exposed before phosphatidyl-
serine, it may facilitate the engulfment of 
dying cells by immature dendritic cells, 
thereby increasing the immunogenicity 
of cell death (Obeid et al., 2007). After 
phosphatidylserine is exposed, in late 
stages of apoptosis, the cell surface 
glycosylation pattern changes, correlat-
ing with the recruitment of membranes 
from cytoplasmic organelles, in par-
ticular the ER, to the cell surface. This 
change in the glycocalix facilitates the 
binding of the opsonins, complement 
factor C1q, C-reactive protein (CRP), the 
long penetraxin (PTX-3), and the col-
lectins (mannan-binding protein [MBL], 
surfactant proteins A and D [SP-A and 
-D]). The alteration of the glycosylation 
pattern of late apoptotic cells may serve 
as a back-up eat-me signal (Schulze et 
al., 2008). If find-me and distinct eat-me 
signals fail and apoptotic cells proceed 
to undergo secondary necrosis and lose 
the integrity of their plasma membrane, 
they can no longer form a synapse-like 
structure with macrophages required for 
the phagocytosis of the entire corpse. 
Reportedly, necrotic cells are engulfed 
through a macropinocytotic-like mecha-
nism (Garg et al., 2009), suggesting that 
the cell death modality determines how 
dead cells are degraded and antigens 
contained in them are presented.
The clearance of stressed and dying 
cells can also be facilitated by the down-
regulation of “don’t eat-me” signals (such 
as CD31 and CD47) that usually assure the 
repulsion of phagocytes (Table S1). Thus, 
there is a whole repertoire of eat-me and 
don’t eat-me signals that are exposed in 
a cell death subroutine-dependent (and 
cell type-specific) fashion and that act 
on a variety of engulfment-promoting 
and -inhibitory receptors, respectively. 
Some of these receptors are expressed 
on specific subsets of engulfing cells, 
suggesting a combinatorial interplay of 
receptor-ligand interactions in which the 
dying cell “chooses” the engulfing cell in 
its vicinity (Figure 1B).
“Hidden Molecules” as Inflammatory 
Signals
In developmental or homeostatic cell 
death, the agonizing cells are efficiently 
cleared before their plasma membranes 
become permeabilized and molecules 
that are usually inaccessible (“hidden”) 
are released or exposed. For instance, 
a yet unknown preformed molecule that 
remains associated with necrotic cells 
(and hence is likely a part of the insolu-
ble cytoskeleton) serves as a ligand for 
the SYK-coupled C-type lectin receptor 
Clec9a. Clec9a is expressed on CD8α+ 
dendritic cells that stimulate the cross-
presentation of antigens associated with 
dead cells (Sancho et al., 2009).
Necrotic cells release several alarm-
ins, which are soluble proteins with 
proinflammatory properties. SAP130 is 
a spliceosome component that is liber-
ated from necrotic cells and activates 
the C-type lectin receptor Mincle, which 
stimulates the recruitment of neutrophils 
to the site of cell death (Yamasaki et al., 
2008). Necrotic cells also release heat 
shock proteins (such as HSP70, HSP90, 
and gp96), in particular when they have 
been previously upregulated in response 
to stress. These then stimulate the pat-
tern recognition receptors TLR2 and 
TLR4. Calgranulins comprise three pro-
teins, S100A8 (calgranulin A), S100A9 
(calgranulin B), and S100A12 (calgranulin 
C), that are predominantly released by 
necrotic neutrophils, monocytes, and 
activated macrophages, respectively, 
and stimulate TLR4 or RAGE (receptor 
for advanced glycation end-products). 
IL-1α can be passively released from 
necrotic cells and stimulate inflam-
mation. N-formylated mitochondrial 
peptides synergize with mitochondrial 
transcription factor A (TFAM), the mito-
chondrial homolog of HMGB1, to induce 
IL-8 release from monocytes (Table S1). 
High-mobility group box 1 (HMGB1) pro-
tein is a nuclear protein that is released 
via the cytoplasm into the microenviron-
ment of dying cells when their plasma 
membrane ruptures. HMGB1 release is 
often more efficient when it occurs in pri-
mary necrosis as opposed to secondary 
necrosis (that is, necrosis after apopto-
sis) (Bianchi, 2009). Moreover, apopto-
sis-associated redox reactions can oxi-
dize and inactivate HMGB1 (Kazama et 
al., 2008). These reports imply that, in 
“normal” apoptosis, HMGB1 is retained 
in the nucleus or released in an inactive 
form when the cells switch to second-
ary necrosis. This contrasts with the 
observation that HMGB1 released from 
anthracylin-treated cancer cells can 
activate TLR4 (Apetoh et al., 2007).
Depending on the molecules that it 
binds to, HMGB1 preferentially inter-
acts with different pattern recognition 
receptors. HMGB1 can form highly 
inflammatory complexes with single-
stranded DNA, lipopolysaccharide, 
IL-1β, and nucleosomes, which interact 
with TLR9, TLR4, IL-1R, and TLR2 recep-
tors, respectively. In addition, uncom-
plexed HMGB1 can interact with RAGE 
(Bianchi, 2009) and TLR4 (Apetoh et al., 
2007). As a result, extracellular HMGB1 
activates macrophages and dendritic 
cells and promotes neutrophil recruit-
ment. It also plays a major role in septic 
shock, an extreme systemic inflamma-
tion in which massive cell death corre-
lates with an increase in serum HMGB1 
levels (Bianchi, 2009).
Necrotic cells also release RNA 
(which stimulates TLR3) and genomic 
double-stranded DNA (dsDNA). Ectopic, 
extranuclear dsDNA stimulates TLR9 
and other pattern recognition receptors 
including RIG-I and MDA5 for the acti-
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vation of IRF3 and NF-κB (leading to the 
production of IFN-β and CXCL10), as 
well as the AIM2 inflammasome (which 
facilitates the secretion of IL-1β) (Kawai 
and Akira, 2009). Thus, dsDNA from 
dying cells that have not been correctly 
disposed of can elicit multiple redundant 
alarm signals and must be degraded to 
avoid pathogenic inflammation. Indeed, 
deficiency for the extracellular DNase I 
causes a lupus-like syndrome in mice, 
and DNase I mutations in humans are 
associated with lupus (Martinez Valle et 
al., 2008). Deficiencies in the intracellu-
lar DNase II also cause polyarthritis in 
mice (Nagata et al., 2010). It is currently 
unknown whether so-called “extracel-
lular traps,” which are produced by 
dying neutrophils or mast cells and 
consist of a chromatin-DNA backbone 
with attached antimicrobial peptides 
and enzymes that trap and kill microbes 
(Wartha and Henriques-Normark, 2008), 
activate pattern recognition receptors 
or whether their particular architecture 
precludes such a process. Other fac-
tors released from necrotic cells include 
monosodium urate microcrystals that 
form when uric acid (soluble within 
cells) precipitates in the sodium-rich 
extracellular fluid. Monosodium urate 
crystals stimulate the inflammasome of 
macrophages and dendritic cells (Marti-
non et al., 2009) and may contribute as 
an endogenous adjuvant to increase the 
immunogenicity of necrotic cells (Kono 
and Rock, 2008).
It would be an oversimplification, 
though, to postulate that all hidden mol-
ecules are proinflammatory in nature. 
For instance, human neutrophils contain 
high concentrations of the four human 
neutrophil peptides (HNP) 1–4, a series 
of α-defensins that are stored in the 
azurophilic granules and are released 
upon apoptotic or necrotic cell death 
to inhibit the secretion of inflammatory 
cytokines and nitric oxide from mac-
rophages (Miles et al., 2009). Moreover, 
HMGB1 (as well as HSP70 and HSP90) 
can engage inhibitory receptors such 
as CD24 that dampen their proinflam-
matory effects (Chen et al., 2009). This 
implies that, depending on the specific 
context, hidden molecules can trigger 
both stimulatory and regulatory recep-
tors that trigger and limit inflammation, 
respectively (Figure 1C).
Stress before Death
Different stressors elicit a limited pattern 
of apparently homogeneous lethal mor-
photypes, mostly apoptosis and necro-
sis. However, cellular stress responses—
which precede cell death—are highly 
diversified, meaning that the history of 
the preapoptotic events conditions the 
internal composition and even the sur-
face characteristics of cellular corpses. 
Moreover, the apoptotic and necrotic 
execution phase itself can involve the 
variable contribution of distinct cata-
bolic hydrolases including caspases 
and caspase-independent death effec-
tors, implying that similar morphologies 
may have been acquired through distinct 
biochemical routes, thereby influencing 
the exposure and release of cell death-
associated molecules.
Heat Shock Proteins
The transcriptional upregulation of heat 
shock proteins (HSPs) is part of the gen-
eral response to cellular stress. Certain 
inducible HSPs such as HSP70 and 
HSP90 can translocate to the plasma 
membrane (HSP70 through binding to 
phosphatidylserine and the sphingolipid 
Gb3) and then serve as danger signals. 
HSPs may facilitate the interaction with 
surface receptors of antigen-presenting 
cells (such as CD91, LOX1, CD40) and 
reportedly mediate the transfer of anti-
genic peptides from the stressed cell 
to the antigen-presenting cell (Table 
S1). HSPs stimulate TLR4, and HSP70 
reportedly stimulates dendritic cell mat-
uration by upregulating CD40 and CD86. 
Moreover, the anticancer agent bort-
ezomib (a proteasome inhibitor) induces 
the expression of HSP90 on the surface 
of dying human myeloma tumor cells, 
facilitating their recognition by dendritic 
cells and the generation of antitumor T 
cells (Spisek et al., 2007). These exam-
ples illustrate how a stress response can 
increase the proinflammatory and immu-
nogenic properties of agonizing cells.
ER Stress Response
The ER stress has been involved in the 
lipotoxic death of macrophages, for 
instance in morbid obesity and within 
atherosclerotic lesions. Alleviation of 
ER stress by a chemical chaperone or 
knockout of the fatty acid-binding pro-
tein-4 (aP2), which is specific to anti-
gen-presenting cells, prevents lipotoxic 
macrophage death and atherosclerosis 
(Erbay et al., 2009). In response to some 
cell death inducers including ionizing 
irradiation and chemotherapeutic agents 
(such as anthracyclins or oxaliplatin), 
cells can mount an ER stress response 
that culminates in the phosphorylation of 
eIF2α (eukaryotic initiation factor 2α) by 
the kinase PERK and the later caspase-
8-mediated cleavage of the ER protein 
BAP31, causing the anterograde traffic 
of calreticulin-containing vesicles from 
the ER to the Golgi apparatus and exo-
cytosis-mediated calreticulin exposure 
(Panaretakis et al., 2009). Preapoptotic 
exposure of calreticulin is an important 
signal for immunogenic cell death (Obeid 
et al., 2007), perhaps because cells that 
expose calreticulin before they expose 
phosphatidylserine are preferentially tar-
geted to immature dendritic cells rather 
than to macrophages. Multiple viruses 
can inhibit the calreticulin exposure 
pathway, perhaps as a strategy for the 
avoidance of immune responses.
Lysosomal Membrane Permeabiliza-
tion and Inflammasome Activation
The terms pyroptosis and pyronecrosis 
have been introduced to describe a par-
ticular form of cell death in macrophages 
that is induced by bacterial infection, is 
accompanied by caspase-1 activation, 
and hence leads to the release of pyro-
genic interleukins, in particular IL-1β, 
whose precursors must be cleaved by 
caspase-1 to be released (Kepp et al., 
2010). Caspase-1 activation relies on 
the stimulation of the inflammasome. 
Activation of the inflammasome can be 
triggered by lysosomal membrane per-
meabilization (LMP), for instance in mac-
rophages that phagocytose silica par-
ticles (the causative agent of silicosis), 
aluminum salt crystals (one of the most 
widely used adjuvants), or microglial 
cells that incorporate the fibrillar peptide 
amyloid-β (whose accumulation plays a 
major role in Alzheimer’s disease). LMP, 
which is a frequent initiating event of 
cell death, culminates in the lysosomal 
release of cathepsin B, which activates 
the NLRP3 inflammasome and hence 
stimulates the production of proinflam-
matory IL-1β (Martinon et al., 2009). 
Intriguingly, caspase-1 activation is also 
involved in the unconventional secre-
tion of multiple leaderless proteins such 
as pro-IL-1α, thioredoxin (important for 
inflammation), fibroblast growth factor 
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(FGF)-2 (important for tissue repair and 
angiogenesis), and calreticulin (important 
for wound healing) (Keller et al., 2008), 
suggesting that cell death preceded by 
caspase-1 activation would be particu-
larly efficient in stimulating inflammation 
and tissue repair.
DNA Stress Response
The DNA damage response (DDR) can 
be stimulated by ionizing irradiation, by 
genotoxic agents including some che-
motherapeutic agents, as well as by 
oncogenic stress. Indeed, the unsched-
uled activation of oncogenes induces a 
DDR that ultimately leads to the activa-
tion of molecules (such as the kinases 
ATM and CHK2 and the tumor suppres-
sor protein p53) that trigger apoptosis 
or senescence (see below) unless they 
are inactivated. This “intrinsic barrier” 
can obstruct oncogenesis and is backed 
up by an “extrinsic barrier” in which the 
DDR stimulates the surface expression 
of NKG2D ligands. NKG2D, a well-char-
acterized stimulatory receptor that is 
expressed by natural killer (NK) cells and 
some T cells, recognizes such ligands, 
stimulating the lysis of the tumor cells 
and hence erecting part of the extrin-
sic barrier. The DDR also induces the 
expression of another NK cell receptor 
ligand, CD155, and that of death recep-
tor 5 (DR5), a receptor of TRAIL (Rau-
let and Guerra, 2009). It remains to be 
determined in which specific circum-
stances the innate immune response is 
elicited by incipient tumors that activate 
(and eventually succumb to) the DDR as 
a result of oncogenic stress. Moreover, 
it remains elusive whether this innate 
reaction contributes to chronic inflam-
mation (and hence stimulates neoplas-
tic transformation) or rather facilitates a 
subsequent cognate anticancer immune 
response (and hence contributes to anti-
cancer immunosurveillance).
Senescence
Senescence is a near-to-irreversible 
arrest of the cell cycle in the G1 phase that 
can precede cell death. The conditional 
reactivation of p53 in hepatocellular car-
cinomas induces cellular senescence, 
followed by the elimination of tumor cells 
by innate immune effectors. Gadolinium 
chloride (a macrophage toxin), as well 
as neutralizing antibodies to suppress 
neutrophil or NK cell function, delayed 
Figure 2. A Combinatorial Code Links Cell Death to the Outcome of Inflammation
(A) The path from cell death to inflammation. The peculiar characteristics of the dying cells determine the nature of the cell death-associated molecules that are 
exposed or released. These molecules mediate the effects of dying cells on the microenvironment, in particular the choice and the activation of the engulfing 
cells and possible effects on bystander cells, thus determining the outcome of inflammation. 
(B) Peculiarities of immunogenic cell death. Dying cells expose calreticulin at an early stage of the apoptotic process, which facilitates engulfment by dendritic 
cells. HMGB1 released from dying cells binds to TLR4 on dendritic cells, thus favoring antigen cross-presentation and upregulating pro-interleukin-β (pro-IL-1β). 
ATP liberated from dying cells binds to the purinergic receptor P2RX7 on dendritic cells, activates the NLRP3 inflammasome, and stimulates the liberation of 
IL-1β, which polarizes CD8+ T cells toward interferon-γ production. A hypothetical dendritic cell maturation factor remains to be characterized.
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tumor regression following p53 reacti-
vation (Xue et al., 2007), indicating that 
p53-induced senescence can stimulate 
an effective anticancer response that is 
mediated by innate immune effectors. 
Senescent cells can upregulate inter-
cellular adhesion molecule 1 (ICAM1) 
as well as NKG2D ligands (Raulet and 
Guerra, 2009), but it is currently unknown 
whether this is the mechanism through 
which senescent cells are destroyed by 
innate immune effectors. Senescent cells 
also express a series of cytokines such 
as IL-6, IL-8, GROα, and TGF-β, which 
interact with their respective receptors 
in an autocrine fashion to maintain the 
cells in the senescent stage and might 
exert paracrine effects on inflammatory 
cells or innate immune effectors (Bartek 
et al., 2008). It is unclear whether this 
“senescence-associated secretory phe-
notype” (SASP) links cellular senescence 
to organismal aging (Franceschi et al., 
2007). Moreover it is not known whether 
SASP stimulates tumor progression or 
rather contributes to the elimination of 
senescent (and potentially oncogenic) 
cells by innate immune effectors.
Autophagy Preceding Death
Macroautophagy (hereafter referred to 
as “autophagy”) is frequently activated 
in response to cellular stress before cells 
die, including in developmental cell death. 
Autophagy is essential for the mainte-
nance of intracellular ATP levels (and pos-
sibly for its release), the secretion of the 
find-me signal lysophosphatidylcholine, 
and the efficient exposure of the eat-me 
signal phosphatidylserine, implying that 
autophagy determines the kinetics of 
corpse removal (and perhaps the nature 
of the phagocyte) (Levine and Kroemer, 
2008). Autophagy within dying antigen 
donor cells can improve the cross-pre-
sentation of tumor antigens or viral anti-
gens by dendritic cells perhaps because 
autophagosomes ferry antigens to den-
dritic cells through an as yet unknown 
mechanism (Li et al., 2008) or because 
higher amounts of type I interferon are 
induced (Uhl et al., 2009). Autophagy may 
also influence the surface proteome of 
dying cells and stimulate the preapop-
totic secretion of HMGB1 (Thorburn et al., 
2009). In this context, it appears intriguing 
that many virus-encoded proteins inhibit 
the autophagic machinery (Orvedahl and 
Levine, 2009), a strategy that might sub-
vert antiviral immune responses. More-
over, many oncogenes, as well as the 
inactivation of tumor suppressor genes, 
result in autophagy inhibition, especially 
in early oncogenesis (Levine and Kro-
emer, 2008), thus constituting a mecha-
nism that might facilitate the escape of 
transformed cells from immunosurveil-
lance. There are multiple intersections 
between autophagy and inflammation 
(Virgin and Levine, 2009). For example, the 
IKK complex, which mediates proinflam-
matory NF-κB activation, is also required 
for the induction of autophagy (Criollo 
et al., 2010). It remains unclear to what 
extent and through which mechanisms 
the increase in longevity mediated by the 
induction of autophagy at the whole-body 
level (by caloric restriction, rapamycin, 
resveratrol, or spermidine) (Morselli et al., 
2009) is accompanied by a reduction of 
inflammation associated with aging.
A Combinatorial Code?
With regard to cell death, the teleologi-
cal purpose of inflammation is to clear 
corpses, to stimulate the replacement 
of lost cells, to detect cell death induced 
by infectious agents, to alert the host 
defense, and possibly to strengthen the 
exogenous barrier against oncogenesis 
(Figure 2A). The preapoptotic phase of 
lethal pathways and frustrated attempts 
to cope with stress have a profound effect 
on the cell surface proteome. These 
factors may affect the cellular release 
of find-me signals, exposure of eat-me 
signals, disclosure of hidden molecules, 
and secretion of cytokines. Together, the 
release of positive and negative chemot-
actic signals and the ensemble of chang-
ing cell surface structures influence the 
choice of the engulfing cell, its activa-
tion, and subsequent differentiation.
Dying and engulfing cells interface, 
first by building a sort of intercellular syn-
apse through a zipper-like mechanism 
(at least in the case of apoptosis), then 
by juxtaposing phagocytic cargo (from 
the engulfed cell) with endocytic pat-
tern recognition receptors (such as the 
RNA- and DNA-sensing TLRs from the 
engulfing cells). This suggests that the 
engulfing cell can detect multiple prop-
erties of the dying or dead cell simul-
taneously. Indeed, it is essential that 
PAMPs (Blander and Medzhitov, 2006) or 
cell death-associated molecules (Obeid 
et al., 2007) are closely associated with 
dying cells so that they are taken up 
together by the same dendritic cell. If 
the PAMP or the cell death-associated 
molecule is present in the environment 
on unrelated cells, it fails to elicit efficient 
antigen presentation, underscoring the 
importance of signal context.
The simultaneous detection of mul-
tiple properties of dying and dead cells 
within the same compartment enables 
the primary inflammatory cell, the mac-
rophage, or the immature dendritic cell 
to decrypt the information by sensing 
multiple cell death-associated molecules 
(and, if present, PAMPs) and to mount an 
appropriate response (Figure 2A). For 
example, the preapoptotic exposure of 
calreticulin, the apoptotic secretion of 
ATP, and the postapoptotic release of 
HMGB1 are all required for dying cells 
to stimulate the presentation of dead 
cell antigens by dendritic cells and 
the polarization of the T cell response 
toward the production of IFN-γ, which is 
essential for efficient antiviral and anti-
tumor immune responses (Apetoh et al., 
2007; Ghiringhelli et al., 2009; Obeid et 
al., 2007). Intriguingly, in this scenario 
the most abundant ER protein (calreti-
culin), one of the most abundant intra-
cellular metabolites (ATP), and the most 
abundant nonhistone chromatin-binding 
proteins (HMGB1) act in an ectopic loca-
tion to compose a spatiotemporal code 
that translates cell death into a cognate 
immune response (Figure 2B).
We speculate that this code regulates 
the relationship between dying cells and 
their microenvironment. A combinato-
rial code would unite several cell death-
associated molecules in a spatiotempo-
rary sequence that—within the context 
of signals originating from surrounding 
cells—then unleashes the silent clear-
ance of dead cells, distinct tissue repair 
responses, recruitment of additional 
inflammatory effectors, or immune reac-
tions (Figure 2A). In this view genetic defi-
ciencies or acquired defects that perturb 
the appropriate interpretation of this com-
binatorial code would give rise to major 
perturbations in tissue homeostasis lead-
ing to insufficient, excessive, or maladap-
tive inflammatory and immune reactions 
(Table S2). Resolving the many remain-
ing mysteries of this code constitutes the 
challenge for future investigation.
804 Cell 140, March 19, 2010 ©2010 Elsevier Inc.
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